计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 ,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Information
Bimiralisib (PQR309) is a novel brain-penetrant dualPI3K/mTORinhibitor with in vitro and in vivo antilymphoma activity. It displays excellent selectivity versus PI3K-related lipid kinases, protein kinases and unrelated targets.
Targets
PI3Kα (Cell-free assay); PI3Kβ (Cell-free assay); mTOR (Cell-free assay); PI3Kγ (Cell-free assay); PI3Kδ (Cell-free assay) 1.5 nM(Kd); 11 nM(Kd); 12 nM(Kd); 25 nM(Kd); 25 nM(Kd)
In vitro
PQR309 shows in vitro activity with a median IC50 value of 233 nmol/L (95% CI, 174-324 nmol/L) in most of the tesed lymphoma cell lines (increasing doses, 72 hours). The arrest in proliferation is mainly due to cell cycle arrest with a block in G1 rather than to apoptosis, limited to only 2/7 cell lines. PQR309 is more active in B-cell lymphoma cell lines (DLBCL, MCL, CLL, and SMZL) than in the T-cell derived ALCL. PQR309 inhibits PI3K/mTOR signaling in lymphoma cell lines. It has in vitro and in vivo antilymphoma activity as single agent and in combination.\xa0
In vivo
PQR309 is orally available, crosses the blood−brain barrier, and displayed favorable pharmacokinetic parameters in mice, rats, and dogs. It shows little clearance when exposed to rat, dog, and human liver microsomes, with a quicker turnover of PQR309 in mouse liver microsomes, where 40% of the compound was eliminated within 30 min. In female mice, plasma concentrations of PQR309 depended on the drug administration route, resulting in half-lives of approximately 13-36 min for po administration vs 9-10 min for iv administration. PQR309 shows excellent oral bioavailability (>50%). Male Beagle dogs, exposed to PQR309 at 10 mg/kg po, showed maximal drug plasma concentrations Cmax of 583 ng/mL (approximately 1.5 μM) after 60-90 min and a half-life of >7 h, which results in drug levels of approximately 0.38 μM (150 ng/mL) after 24 h. The oral bioavailability in male Beagle dogs was estimated to be 23%. Altogether the PK studies in the three models (female CD-1 mouse, female Sprague-Dawley rats, male Beagle dog) show rapid absorption of PQR309 and good oral bioavailability. PQR309 demonstrates efficiency in inhibiting proliferation in tumor cell lines (PC3 prostate cancer cells) and a rat xenograft model (PC3 xenograft model).
Cell Research(from reference)
Cell lines:lymphoma cell lines
Concentrations:500 nmol/L
Incubation Time:72 h
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 三嗪类 |
| 亚类(Subclass) | 氨基三嗪类 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 1,3,5-三嗪-2,4-二胺 |
| 其他上位类(Alternative Parents) | 二烷基芳胺 氨基吡啶及其衍生物 吗啉 咪唑内酰胺类 1,3,5-三嗪 杂芳族化合物 氧环化合物 二烷基醚 氮杂环化合物 伯胺 有机氟化物 碳氢化合物衍生物 烷基氟化物 |
| 分子骨架(Molecular Framework) | 芳香族杂单环化合物 |
| 取代基(Substituents) | 1,3,5-三嗪 - 2,4-二氨基-s-三嗪 - 氟化烷基 - 烷基溴化物 - 氨基酸 - 氨基吡啶 - 芳香族杂单环化合物 - 氮杂环 - 二烷基醚 - 二烷基芳基胺 - 乙醚 - 杂芳香族化合物 - 烃衍生物 - 咪唑内酰胺 - Morpholine - 有机硝基化合物 - 有机氧化合物 - 有机氟化物 - 有机卤化物 - 有机氮化合物 - 有机氧化合物 - 氧杂环 - 氧杂吡嗪烷 - 初级胺 - 吡啶 - 三芳基胺 |
| 描述(Description) | 该化合物属于有机化合物中的1,3,5-三嗪-2,4-二胺类。这类芳香化合物含有1,3,5-三嗪环,其2,4位被胺基团取代。 |
| 外部描述符(External Descriptors) | 暂无 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|